My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cassava Sciences, Inc. - Common Stock
(NQ:
SAVA
)
3.050
+0.730 (+31.48%)
Streaming Delayed Price
Updated: 12:53 PM EDT, Sep 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cassava Sciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Keep an eye on the top gainers and losers in Tuesday's session.
Today 12:30 EDT
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
These stocks are gapping in today's session
Today 10:30 EDT
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Cassava Sciences (SAVA) Stock Is Surging Tuesday: What's Going On?
Today 10:19 EDT
Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Today 8:09 EDT
Via
Benzinga
Looking Into Cassava Sciences's Recent Short Interest
February 03, 2025
Via
Benzinga
Unpacking the Latest Options Trading Trends in Cassava Sciences
November 26, 2024
Via
Benzinga
Why Super League Enterprise Shares Are Trading Higher By 200%; Here Are 20 Stocks Moving Premarket
Today 5:41 EDT
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 22, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
September 22, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Cassava Sciences Posts Q2 Loss on Pivot
August 14, 2025
Via
The Motley Fool
Topics
Intellectual Property
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
March 25, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful
March 25, 2025
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by...
Via
Stocktwits
Which stocks are experiencing notable movement on Tuesday?
March 25, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 25, 2025
Via
Benzinga
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
March 25, 2025
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
Via
Benzinga
Which stocks are moving before the opening bell on Tuesday?
March 25, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
March 03, 2025
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...
Via
Benzinga
Top Biotech Short Squeeze Stocks
December 12, 2024
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
December 04, 2024
Via
Benzinga
S&P 500, Nasdaq Hit Record Highs To Start December
December 02, 2024
Stocks are a mixed bag this afternoon, with the S&P 500 Index and Nasdaq Composite earlier touching fresh record highs as the latter jumps triple digits.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
Benzinga Bulls And Bears: Amazon, Tesla, Rivian, Palantir And How Dogecoin Helped Low-Income Families Achieve Homeownership
November 30, 2024
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Via
Benzinga
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
November 26, 2024
Via
Benzinga
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
November 25, 2024
SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 25, 2024
Via
Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
November 25, 2024
Via
Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
November 25, 2024
Via
Benzinga
Topics
Economy
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
November 25, 2024
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.
Via
Benzinga
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings
November 25, 2024
Via
Benzinga
Topics
Stocks
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
November 25, 2024
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.